risperidone

GPTKB entity

Statements (55)
Predicate Object
gptkbp:instanceOf antipsychotic medication
gptkbp:approvalYear 1993
gptkbp:approvedBy gptkb:FDA
gptkbp:ATCCode N05AX08
gptkbp:brand gptkb:Risperdal_Consta
gptkb:Risperdal
gptkbp:CASNumber 106266-06-2
gptkbp:chemicalFormula C23H27FN4O2
gptkbp:contraindication hypersensitivity to risperidone
gptkbp:developedBy gptkb:Janssen_Pharmaceutica
gptkbp:discoveredIn 1984
gptkbp:drugClass benzisoxazole derivative
gptkbp:eliminationHalfLife 3-20 hours
gptkbp:excretion gptkb:kidney
gptkbp:genericAvailable true
https://www.w3.org/2000/01/rdf-schema#label risperidone
gptkbp:interactsWith gptkb:CNS_depressants
CYP2D6 inhibitors
antihypertensive drugs
gptkbp:legalStatus prescription only
gptkbp:marketedAs 1994
gptkbp:mechanismOfAction dopamine D2 receptor antagonist
serotonin 5-HT2A receptor antagonist
gptkbp:metabolism gptkb:paliperidone
liver
gptkbp:patentExpired 2003
gptkbp:pregnancyCategory C (US)
B3 (Australia)
gptkbp:prescribes adults
children
elderly
gptkbp:proteinBinding 90%
gptkbp:riskFactor neuroleptic malignant syndrome
tardive dyskinesia
stroke in elderly with dementia
gptkbp:routeOfAdministration oral
intramuscular injection
gptkbp:sideEffect anxiety
constipation
dizziness
weight gain
drowsiness
extrapyramidal symptoms
increased prolactin
gptkbp:synonym gptkb:Risperdal_Consta
gptkb:Risperdal
gptkbp:usedFor bipolar disorder
schizophrenia
irritability associated with autism
gptkbp:WHOModelListOfEssentialMedicines true
gptkbp:bfsParent gptkb:Invega
gptkb:Risperdal
gptkb:Paul_Janssen
gptkb:Zyprexa
gptkbp:bfsLayer 6